Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RGLS
- Price
- 7.88
- Stock movement up
- +0.02 (0.25%)
- Company name
- Regulus Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 564.95M
- Ent value
- 545.54M
- Price/Sales
- 1870.70
- Price/Book
- 6.51
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -50.96%
- 1 year return
- 223.81%
- 3 year return
- 49.81%
- 5 year return
- -1.56%
- 10 year return
- -39.70%
Last updated: 2025-09-15
DIVIDENDS
RGLS does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1870.70 |
| Price to Book | 6.51 |
| EV to Sales | 1806.41 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 69.23M |
| EPS (TTM) | -0.64 |
| FCF per share (TTM) | -0.56 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 302.00K |
| Gross profit (TTM) | 56.00K |
| Operating income (TTM) | -44.60M |
| Net income (TTM) | -41.63M |
| EPS (TTM) | -0.64 |
| EPS (1y forward) | -1.62 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 18.54% |
| Operating margin (TTM) | -14766.89% |
| Profit margin (TTM) | -13784.11% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 26.37M |
| Net receivables | 0.00 |
| Total current assets | 91.69M |
| Goodwill | 0.00 |
| Intangible assets | 25.00K |
| Property, plant and equipment | 2.05M |
| Total assets | 93.76M |
| Accounts payable | 792.00K |
| Short/Current long term debt | 476.00K |
| Total current liabilities | 6.48M |
| Total liabilities | 6.96M |
| Shareholder's equity | 86.81M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -35.95M |
| Capital expenditures (TTM) | 411.00K |
| Free cash flow (TTM) | -36.36M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -47.96% |
| Return on Assets | -44.40% |
| Return on Invested Capital | -47.96% |
| Cash Return on Invested Capital | -41.89% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 8.15 |
| Daily high | 8.18 |
| Daily low | 8.07 |
| Daily Volume | 0K |
| All-time high | 2649.60 |
| 1y analyst estimate | 7.00 |
| Beta | 0.37 |
| EPS (TTM) | -0.64 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| RGLS | S&P500 | |
| Current price drop from All-time high | -99.69% | -1.00% |
| Highest price drop | -99.97% | -56.47% |
| Date of highest drop | 27 Mar 2023 | 9 Mar 2009 |
| Avg drop from high | -80.01% | -10.99% |
| Avg time to new high | 65 days | 12 days |
| Max time to new high | 2671 days | 1805 days |
COMPANY DETAILS
Marketcap
564.95M
Marketcap category
Small-cap
Description
Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was formerly known as Regulus Therapeutics LLC and changed its name to Regulus Therapeutics Inc. in January 2009. The company was incorporated in 2007 and is based in San Diego, California. As of June 25, 2025, Regulus Therapeutics Inc. operates as a subsidiary of Novartis AG.
Employees
34
Website
Investor relations
-
SEC filings
CEO
Joseph P. Hagan
Country
USA
City
San Diego
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner